Skip to content

Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

CompletedPhase 3NCT01752322
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

Study details

Official title
Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain
Interventions
  • Drug: Lidocaine 5% medicated plaster
  • Drug: Placebo plaster
Sponsor
Grünenthal GmbH
Start date
2012-10
Primary completion
2016-06
Sex
All
Age range
from 18 Years
Results posted
No results posted in this snapshot
Countries
Austria, Belgium, Brazil, Denmark, France, Italy, Spain, United Kingdom
Total sites listed
42

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female subjects aged 18 years or older. * Subjects suffering from moderate to severe localized chronic PoNP (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping). * Localized PoNP present for at least 3 months. * Size of the affected painful skin area is not larger than the size of 3 plasters. * Intact skin besides the scar of surgery in the area of plasters application * Baseline average pain intensity of 4 or greater on the 11 point pain intensity Numeric Rating Scale. Exclusion Criteria: * Participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial. * Previous enrollment in this trial. * History of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment. * Evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation. * Pregnant or breastfeeding women or women of childbearing potential who are sexually active without satisfactory contraception. * Any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment. * Any surgery scheduled or expected during the trial. * Clinically significant disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial. * History of malignancy (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment. * Subject with PoNP related to a surgery due to neoplasia: suspected residual neoplasia or metastases. * Pending litigation due to chronic pain or disability. * Total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention. * Hypersensitivity to the lidocaine 5% medicated plaster, its excipients, or anesthetics of the amide type. * Any former use of topical lidocaine in the area of localized chronic PoNP. * Severe renal, hepatic or heart disorder.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01752322